Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atherosclerosis
Estradiol valerate plus levonorgestrel therapy reduces plasma trans-fatty acid
March 2nd, 2006
Combined estradiol valerate plus levonorgestrel therapy reduces plasma trans-fatty acid levels in postmenopausal women. According to investigators in Finland, "Trans-fatty acids (TFA) have been classified as atherogenic dietary constituents but the effect of hormone replacement therapy (HRT) on their concentrations is not known. We used a washout protocol to study the effect of long-term estrogen and combined estrogen-progestin HRT on plasma elaidate (18:1t), which is the trans isomer of oleate and the major TFA in the diet." "The study group comprised 15 women receiving estradiol valerate HRT and 15 women receiving combined HRT with estradiol...
Source: Women's Health Weekly (2006-03-02)
|
